DD213923A5 - Verfahren zur herstellung neuer diazabicyclo-(3,3,1)-nonane - Google Patents

Verfahren zur herstellung neuer diazabicyclo-(3,3,1)-nonane Download PDF

Info

Publication number
DD213923A5
DD213923A5 DD83254711A DD25471183A DD213923A5 DD 213923 A5 DD213923 A5 DD 213923A5 DD 83254711 A DD83254711 A DD 83254711A DD 25471183 A DD25471183 A DD 25471183A DD 213923 A5 DD213923 A5 DD 213923A5
Authority
DD
German Democratic Republic
Prior art keywords
compounds
formula
prepared
hydrogen
preparation
Prior art date
Application number
DD83254711A
Other languages
German (de)
English (en)
Inventor
Uwe Schoen
Bernd Hachmeister
Wolfgang Kehrbach
Ulrich Kuehl
Gerd Buschmann
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Publication of DD213923A5 publication Critical patent/DD213923A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
DD83254711A 1982-09-18 1983-09-09 Verfahren zur herstellung neuer diazabicyclo-(3,3,1)-nonane DD213923A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823234697 DE3234697A1 (de) 1982-09-18 1982-09-18 Neue diazabicyclo-(3,3,1)-nonane

Publications (1)

Publication Number Publication Date
DD213923A5 true DD213923A5 (de) 1984-09-26

Family

ID=6173602

Family Applications (1)

Application Number Title Priority Date Filing Date
DD83254711A DD213923A5 (de) 1982-09-18 1983-09-09 Verfahren zur herstellung neuer diazabicyclo-(3,3,1)-nonane

Country Status (25)

Country Link
US (2) US4550112A (xx)
EP (2) EP0103833B1 (xx)
JP (2) JPS5970686A (xx)
AT (2) ATE45579T1 (xx)
AU (1) AU564910B2 (xx)
CA (1) CA1254209A (xx)
CS (1) CS389891A3 (xx)
DD (1) DD213923A5 (xx)
DE (3) DE3234697A1 (xx)
DK (1) DK165833C (xx)
ES (1) ES8405398A1 (xx)
FI (1) FI76338C (xx)
GE (1) GEP19960316B (xx)
GR (1) GR78722B (xx)
HU (1) HU191096B (xx)
IE (1) IE57580B1 (xx)
IL (1) IL69751A (xx)
MX (1) MX9202996A (xx)
NO (1) NO160516C (xx)
NZ (1) NZ205627A (xx)
PH (1) PH20768A (xx)
PT (1) PT77344B (xx)
SU (1) SU1272989A3 (xx)
UA (1) UA817A1 (xx)
ZA (1) ZA836185B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529872A1 (de) * 1985-08-21 1987-02-26 Kali Chemie Pharma Gmbh Neue tetraoxoverbindungen
WO1989000158A1 (en) * 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
DE3722134A1 (de) * 1987-07-04 1989-01-19 Kali Chemie Pharma Gmbh 3-sulfonyl-3,7-diazabicyclo(3,3,1)nonan- verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
PT88381B (pt) * 1987-09-09 1995-07-06 Kali Chemie Pharma Gmbh Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel
DE4139763A1 (de) * 1991-12-03 1993-06-09 Kali-Chemie Pharma Gmbh, 3000 Hannover, De Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
DE4421324A1 (de) 1994-06-17 1995-12-21 Kali Chemie Pharma Gmbh Neue 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
US20040229900A1 (en) * 1999-06-16 2004-11-18 Astrazeneca Ab Bispidine compounds useful in the treatment of cardiac arrythmias
US20050004113A1 (en) * 1999-06-16 2005-01-06 Astrazeneca Ab New bispidine compounds useful in the treatment of cardiac arrhythmias
SE9902270D0 (sv) 1999-06-16 1999-06-16 Astra Ab Pharmaceutically active compounds
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
SE0002603D0 (sv) * 2000-07-07 2000-07-07 Astrazeneca Ab New compounds
US6808924B1 (en) 2000-07-11 2004-10-26 Claudia Lanari Mouse mammary tumor lines expressing estrogen and progesterone receptors
AR030756A1 (es) * 2000-10-02 2003-09-03 Astrazeneca Ab Compuesto de oxabispidina util en el tratamiento de arritmias cardiacas
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
DE10131217A1 (de) * 2001-06-28 2003-01-09 Solvay Pharm Gmbh 3-Phenyl-3,7-diazabicyclo 3,3,1 nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
JP2006528155A (ja) * 2003-07-21 2006-12-14 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ３，７−ジアザビシクロ［３．３．１］ノナン化合物の、ヒト男性患者の抗不整脈事象治療及び／又は予防のための使用
WO2005030207A1 (en) * 2003-09-26 2005-04-07 Solvay Pharmaceuticals Gmbh Use of 3, 7-diazabicyclo (3.3.1) nonane compounds for the treatment of brugada syndrome
SE0302775D0 (sv) * 2003-10-20 2003-10-20 Astrazeneca Ab Chemical compound and assay
SE0401540D0 (sv) * 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
SE0401539D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
AU2006258293B2 (en) * 2005-06-13 2010-06-17 Astrazeneca Ab New oxabispidine compounds for the treatment of cardiac arrhythmias
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2428792A1 (de) * 1974-06-14 1976-01-02 Knoll Ag Neue antiarrhythmika
LU76173A1 (xx) * 1976-11-11 1978-07-10
DE2658558A1 (de) * 1976-12-23 1978-06-29 Bayer Ag Diazabicyclo(3,3,1)nonane, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2726571A1 (de) * 1977-06-13 1978-12-21 Basf Ag Neue bispidinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten

Also Published As

Publication number Publication date
EP0250903B1 (de) 1991-11-27
NO160516C (no) 1989-04-26
HU191096B (en) 1987-01-28
SU1272989A3 (ru) 1986-11-23
NO833346L (no) 1984-03-19
FI76338B (fi) 1988-06-30
PT77344B (en) 1986-03-11
EP0103833B1 (de) 1989-08-16
DE3380409D1 (de) 1989-09-21
DK165833C (da) 1993-06-21
EP0250903A2 (de) 1988-01-07
IE832186L (en) 1984-03-18
AU1920683A (en) 1984-03-22
DK422583D0 (da) 1983-09-16
IL69751A0 (en) 1983-12-30
JPS5970686A (ja) 1984-04-21
ATE45579T1 (de) 1989-09-15
JPH05247039A (ja) 1993-09-24
ES525653A0 (es) 1984-06-01
NO160516B (no) 1989-01-16
MX9202996A (es) 1992-07-01
FI833339A (fi) 1984-03-19
JPH0670056B2 (ja) 1994-09-07
ES8405398A1 (es) 1984-06-01
GEP19960316B (en) 1996-06-24
FI76338C (fi) 1988-10-10
US4550112A (en) 1985-10-29
EP0103833A3 (en) 1984-11-28
US4742172A (en) 1988-05-03
CA1254209A (en) 1989-05-16
GR78722B (xx) 1984-10-02
ATE69817T1 (de) 1991-12-15
CA1259998C (xx) 1989-09-26
PT77344A (en) 1983-10-01
PH20768A (en) 1987-04-10
DE3382466D1 (de) 1992-01-09
AU564910B2 (en) 1987-09-03
CS389891A3 (en) 1992-07-15
DK165833B (da) 1993-01-25
FI833339A0 (fi) 1983-09-19
EP0250903A3 (en) 1988-03-09
EP0103833A2 (de) 1984-03-28
DE3234697A1 (de) 1984-03-22
IL69751A (en) 1986-10-31
ZA836185B (en) 1984-04-25
IE57580B1 (en) 1993-01-13
DK422583A (da) 1984-03-19
UA817A1 (uk) 1993-12-15
NZ205627A (en) 1985-11-08

Similar Documents

Publication Publication Date Title
DD213923A5 (de) Verfahren zur herstellung neuer diazabicyclo-(3,3,1)-nonane
EP0005205B1 (de) Substituierte 5,6-Dimethylpyrrolo(2,3-d)pyrimidine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
EP0242851A1 (de) N-(2'-Aminophenyl)-benzamid-Derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung neoplastischer Erkrankungen
EP0019172B1 (de) 6-Substituierte 11-Alkylen-morphantridine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
DE1670305C3 (de) 5-Phenyl-2,4-dioxo-1,2,3,4-tetrahydro-3H-1,5-benzodiazepine und Verfahren zu ihrer Herstellung
DD236928A5 (de) Verfahren zur herstellung neuer 1,2,4-triazolo-carbamate
DE3222096A1 (de) Optisch aktive beziehungsweise racemische trans- und/oder cis-1-(2'-(alkoxycarbonyl)-2'-(hydroxyimino)-aethyl)-1-alkyl-1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)chinolizine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie verfahren zur herstellung von optisch aktiven beziehungsweise racemischen trans- und/oder cis-apovincaminsaeureestern, optisch aktive trans-apovincaminsaeureester und die letzteren enthaltende arzneimittel
DE3134672A1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DE3226921C2 (de) Neue 3,7-Diazabicyclo[3.3.1]nonan Verbindungen und Verfahren zu ihrer Herstellung
AT391866B (de) Verfahren zur herstellung neuer s-triazolo (1,5-a) pyrimidine
DE2730593A1 (de) Neue aminoalkoxybenzofurane, verfahren zur herstellung derselben und diese enthaltende pharmazeutische mittel
DE2346466A1 (de) Neue pyrazolopyridobenzodiazepinone mit ihren salzen
DE2459630C3 (de) 2-Pyrimidyl-aminomethylergolinderivate, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
DE3026584A1 (de) 10-halogen-14-oxon-15-hydroxy-e-homoeburnanderivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
EP0360784A1 (de) Thienyloxy-alkylamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CH658656A5 (de) Neue eburnamenin-14-carbonsaeure-derivate, verfahren zu ihrer herstellung und die neuen verbindungen enthaltende arzneimittelpraeparate.
DE3529872A1 (de) Neue tetraoxoverbindungen
DE1445415C3 (de) Substituierte Imidazolidinone, ihre therapeutisch verträglichen Salze und Verfahren zu ihrer Herstellung
AT360039B (de) Verfahren zur herstellung von neuen n-((1,2,4) oxadiazolo(2,3-a)pyrimidin-(7)) carbamaten
AT379810B (de) Verfahren zur herstellung von neuen 3,7-diazabicyclo (3,3,1) nonanderivaten, deren stereoisomeren und physiologisch vertraeglichen saeureadditionssalzen
CH601253A5 (en) (1)-Benzoyl (2)-dichloro-phenyl-amino (2)-imidazoline
AT309444B (de) Verfahren zur Herstellung von neuen Thieno[2,3-e][1,4]-diazepin-2-onen sowie von den Säureadditionssalzen hievon
DE2760038C2 (xx)
DE2341876A1 (de) Neue 1-(m-acyloxyphenyl)-1-hydroxy- 2-n-alkylamino-aethane, deren saeureadditionssalze, diese enthaltende arzneimittel, sowie verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
RPI Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)